These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20120071)

  • 1. [Methodological approaches to assessment of negative symptoms during pharmacotherapy of schizophrenia].
    Tsygankov BD; Ovsiannikov SA; Khannanova AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(11):101-6. PubMed ID: 20120071
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of computer psychosemantic analysis for diagnosis of possible relapse in patients with schizophrenia in the period of therapeutic remission forming].
    Tiuvina NA; Krivtsov KIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(11):49-52. PubMed ID: 17176604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of the 24-h medication use recall for assessing medication adherence among psychiatric outpatients.
    Adelufosi AO; Ogunwale A
    Asian J Psychiatr; 2013 Feb; 6(1):85. PubMed ID: 23380328
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacotherapy of schizophrenia: ploypharmacy approaches.
    Rahiminejad F; Akhondzadeh S
    Acta Med Iran; 2010; 48(4):203-8. PubMed ID: 21279929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy.
    Nasrallah HA; Dursun SM
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):3-5. PubMed ID: 17046983
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of negative symptoms: pharmacological and methodological issues.
    Carpenter WT
    Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: clozapine--current status and role in the pharmacotherapy of schizophrenia.
    Sharma V
    Can J Psychiatry; 1996 Sep; 41(7):483. PubMed ID: 8884040
    [No Abstract]   [Full Text] [Related]  

  • 10. The evolving definition of treatment resistance.
    Peuskens J
    J Clin Psychiatry; 1999; 60 Suppl 12():4-8. PubMed ID: 10372602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choices in antipsychotic therapy in schizophrenia.
    Frankenburg FR
    Harv Rev Psychiatry; 1999; 6(5):241-9. PubMed ID: 10372289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia.
    Brown LA; Levin GM
    Pharmacotherapy; 1998; 18(1):69-83. PubMed ID: 9469684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
    Buckley PF; Stahl SM
    Acta Psychiatr Scand; 2007 Feb; 115(2):93-100. PubMed ID: 17244172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A discriminant validity study of negative symptoms with a special focus on depression and antipsychotic medication.
    Lewine RR
    Am J Psychiatry; 1990 Nov; 147(11):1463-6. PubMed ID: 1977328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct assessment of functional abilities: relevance to persons with schizophrenia.
    McKibbin CL; Brekke JS; Sires D; Jeste DV; Patterson TL
    Schizophr Res; 2004 Dec; 72(1):53-67. PubMed ID: 15531407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant raloxifene treatment for negative symptoms of schizophrenia.
    Dhandapani A; Narayanaswamy JC; Venkatasubramanian G
    Asian J Psychiatr; 2013 Jun; 6(3):254-5. PubMed ID: 23642987
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia drug gets negative results for negative symptoms.
    Kingwell K
    Nat Rev Drug Discov; 2014 Apr; 13(4):244-5. PubMed ID: 24687052
    [No Abstract]   [Full Text] [Related]  

  • 19. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.
    Leucht S; Davis JM; Engel RR; Kissling W; Kane JM
    Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.